Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny has then
Relocated to the USA, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical topics, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
After authoring seven papers during a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published dozens of experimental research papers and theoretical papers as sole
Writer. Those sole-author articles
Included two important themes.
The first of those focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Verifying their resistance. The outcomes and underlying
Notion were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the publication was
Titled, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author works
Is a research method to develop knowledge via
Uniting a few facts together from seemingly unrelated fields.
This results in new notions with testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Crucial outcome discovered by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others don' t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Preventing organism aging — in other words, “preventing cancer
By remainng young. ” His lab closely collaborated with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Drugs besides rapamycin. The cell culture studies were
Complemented by studies in mice, including several models like
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Misha Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Prolongation and cancer stoppage in mice, and combinations of anti-
Aging medications to be taken by humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.